Wellgistics Health (NASDAQ: WGRX) launches Forzet medical food for GLP-1-related muscle loss
Rhea-AI Filing Summary
Wellgistics Health, Inc. filed a current report highlighting the launch of Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies, including GLP-1 agonist drugs such as Ozempic, Wegovy and Mounjaro.
Forzet is classified as a medical food, is available over the counter, does not require a prescription, and is intended for use under physician supervision. It has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe.
Wellgistics plans to recommend Forzet through its EinsteinRx AI pharmacy hub via point-of-sale pop-ups in its 6,500+ pharmacy network and to feature GLP-1 drugs and Forzet in its growing direct-to-consumer and telehealth offerings. The press release notes estimates that the GLP-1 agonist market could grow from $70 billion in 2025 to $201 billion in 2030.
Positive
- None.
Negative
- None.
Insights
Wellgistics launches Forzet to address GLP-1-related muscle loss within a rapidly expanding market.
Wellgistics Health is introducing Forzet™ as a medical food aimed at muscle loss linked to weight loss therapies, particularly GLP-1 agonists. The product is over-the-counter, classified as a “Food for Special Medical Purposes,” and intended for use under medical supervision rather than as an FDA-approved drug.
The company plans to integrate Forzet into its EinsteinRx AI hub and Wellgistics Pharmacy Network, using point-of-sale recommendations and telehealth channels. This leverages existing connectivity to 6,500+ pharmacies and 200+ manufacturers to promote Forzet alongside GLP-1 prescriptions, while also supporting a direct-to-consumer strategy through its own pharmacy.
The cited estimate that the GLP-1 agonist market may expand from
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On March 9, 2026, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 hereto.
The information in this Item 7.01, including Exhibits 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Report will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1.
The press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. With the exception of historical matters, the matters discussed in the press releases include forward-looking statements within the meaning of applicable securities laws. Such forward-looking statements include, among others, statements regarding the Company’s projects, potential financial performance, and growth opportunities. The words “believes,” “expects,” “intends,” “plans,” “anticipates,” “hopes,” “likely,” “will,” and similar expressions are intended to identify certain of these forward-looking statements. These statements are based on the Company’s expectations and involve risks, uncertainties and other important factors that could cause the actual results performance or achievements of the Company (or entities in which the Company has interests), or industry results, to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause the Company’s actual future results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors could arise. Certain risks regarding the Company’s forward-looking statements are discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”), including an extensive discussion of these risks in the Company’s Registration Statement on Form S-1, declared effective by the SEC on September 25, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements which reflect management’s view only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions or circumstances.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed as part of, or incorporated by reference into, this Report.
| Exhibit No. | Description | |
| 99.1 | Press Release Dated March 9, 2026 | |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 9, 2026 | WELLGISTICS HEALTH, INC. | |
| By: | /s/ Prashant Patel | |
| Prashant Patel, President | ||
Exhibit 99.1
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet™
| ● | GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 | |
| ● | Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs’ primary side effect | |
| ● | Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain |
TAMPA, FL, MARCH 9, 2026 –Wellgistics Health, Inc. (NASDAQ: WGRX) (“Wellgistics”), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs. Forzet’s proprietary formulation has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe. Forzet will initially be be made available through the Company’s affiliated pharmacy and select members of the Wellgistics Pharmacy Network. Forzet is classified as a medical food intended for the dietary management of muscle loss associated with weight loss therapies under physician supervision. Forzet is not an FDA-approved drug, is available over the counter and does not require a prescription.
“Forzet is indicated for the dietary management of muscle loss associated with weight loss therapies,” said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. “GLP-1 agonist drugs such as Ozempic®, Wegovy®, Mounjaro® and others are members of the fastest growing class of drugs worldwide because of myriad benefits that result from losing weight. While the benefits of the weight loss associated with GLP-1 agonist therapy can no longer be denied, it remains the case that a significant amount of that weight loss comes from loss of muscle. As such, the Company believes there may be a significant market opportunity for a medical food product that distinguishes itself from dietary supplements by virtue of its extensive clinical data package in sarcopenia associated with other muscle loss-related medical conditions and -stringent cGMP manufacturing requirements.”
1 https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
Mr. Patel continued, “We intend to leverage Forzet’s unique value proposition by recommending it as an adjunct solution for patients prescribed GLP-1 agonist drugs via pop-ups through our EinsteinRx hub technology at the point-of-sale in Wellgistics Pharmacy Network pharmacies. Additionally, as we build out our own telehealth customer base where we can more fully service patients through our own Wellgistics Pharmacy both in-store and online, we intend to make GLP-1 drug and related solutions such as Forzet a central feature of our direct-to-consumer (DTC) offering in order to drive loyalty by way of unique product offering as we begin to expand our DTC efforts.”
“My practice primarily addresses patients seeking weight loss therapies,” said Dr. Vivek Bansal, MD MPH, Triple Board-Certified Endocrinologist and Founder of The EnLyv Clinics in Bridgewater, NJ. “We have been working through myriad products seeking to address muscle loss while on current weight loss therapies, and believe Forzet represents a unique solution that has worked well in other sarcopenia-related medical conditions. We are excited to make this available to our patients.”
Dr. Bansal is an independent physician and has not been compensated by Wellgistics for this statement.
The GLP-1 agonist market is expected to grow from $70 billion in 2025 to $201 billion in 20301 according to Grandview Research. The market growth is driven by drugs with increasing potency to induce weight loss, more convenient oral formulations that help drive adoption as well as increasing interest from non-obese patients looking for weight loss alternatives to diet & exercise. Limiting factors for the expansion of the GLP-1 market include side effects such as muscle loss and gastrointestinal challenges.
Ozempic®, Wegovy®, and Mounjaro® are registered trademarks of their respective owners. Wellgistics Health, Inc. is not affiliated with or endorsed by the manufacturers of these products.
About FORZET™2
Product Description: Medical Food for the dietary management of muscle loss associated with weight loss therapies.
Classification: “Food for Special Medical Purposes” in accordance with section 5 (b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3). Nutritional requirement caused by a specific medical condition. For use under medical supervision.
2 https://tollohealth.com/forzet/
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the “Wellgistics Pharmacy Network”) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.
For more information, visit www.wellgisticshealth.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet™, the expected benefits of the product, the Company’s plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Company’s direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “continue,” or the negative of these terms or other comparable terminology.
Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Company’s products and services, the Company’s ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Company’s filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzet™ is intended to diagnose, treat, cure, or prevent any disease.
Wellgistics Media & Investor Contact
Media:
media@wellgisticshealth.com
Investor
Relations:
IR@wellgisticshealth.com
FAQ
What did Wellgistics Health (WGRX) announce in its latest 8-K filing?
What is Forzet™ and how is it classified by Wellgistics Health (WGRX)?
How does Wellgistics (WGRX) plan to distribute and promote Forzet™?
What market opportunity does Wellgistics (WGRX) see for Forzet™ with GLP-1 therapies?
What clinical background does Wellgistics (WGRX) report for Forzet™?
How does Forzet™ fit into Wellgistics Health (WGRX) technology platforms?
Filing Exhibits & Attachments
7 documents